SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The March 2023 quarter revenue stood at Rs. 3100.64 millions, up 11.99% as compared to Rs. 2768.65 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2023 is Rs. -1438.35 millions as compared to Net Profit of Rs. 173.32 millions of corresponding quarter ended March 2022Operating profit Margin for the quarter ended March 2023 slipped to -49.43% as compared to 215.70% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 3100.64 2768.65 11.99 10724.32 9429.27 13.73 10724.32 9429.27 13.73
Other Income 37.88 90.78 -58.27 418.48 420.68 -0.52 418.48 420.68 -0.52
PBIDT -49.43 215.70 -122.92 -510.65 -14.86 3336.41 -510.65 -14.86 3336.41
Interest 29.32 5.77 408.15 93.80 20.74 352.27 93.80 20.74 352.27
PBDT -1155.17 209.93 -650.26 -1731.09 -35.60 4762.61 -1731.09 -35.60 4762.61
Depreciation 283.18 212.68 33.15 1059.79 831.88 27.40 1059.79 831.88 27.40
PBT -1438.35 -2.75 52203.64 -2790.88 -867.48 221.72 -2790.88 -867.48 221.72
TAX 0.00 -176.07 0.00 206.12 -313.18 -165.82 206.12 -313.18 -165.82
Deferred Tax 0.00 -176.07 0.00 206.12 -315.55 -165.32 206.12 -315.55 -165.32
PAT -1438.35 173.32 -929.88 -2997.00 -554.30 440.68 -2997.00 -554.30 440.68
Equity 140.81 140.81 0.00 140.81 140.81 0.00 140.81 140.81 0.00
PBIDTM(%) -1.59 7.79 -120.46 -4.76 -0.16 2921.32 -4.76 -0.16 2921.32

Unichem Lab Share Price

345.00 -5.85 (-1.67%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×